

## Arch Capital

### Strong Franchise with Macro Tailwinds

**ACGL's 2Q24 results were better than assumed, driven by upside in underwriting margins and investment income.** We maintain a Neutral rating due to valuation, but consider ACGL a premier reinsurance franchise and the best name for investors seeking to take advantage of hard reinsurance pricing.

- **EPS upside; raising estimates.** ACGL reported 2Q24 operating EPS of \$2.57, significantly above our \$2.05 estimate and consensus of \$2.18. Compared to our model, the beat was primarily due to better margins and a lower underlying loss ratio. Other items that contributed included: higher investment income (\$0.04 per share after taxes), more favorable prior-year development (+\$0.02), lower cat losses (+\$0.01 variance), and lower tax rate (+\$0.10 per share). We are raising our 3Q24 EPS forecast from \$1.72 to \$1.76 and our 2025 projection from \$8.63 to \$8.83, mostly to reflect higher future investment income.
- **Business fundamentals were strong.** Reinsurance results were marked by higher than assumed margins (CR 79.5% vs. our 84.7% estimate) and premiums (+14% versus our -3% estimate). Margins were helped by lower attritional losses, which more than offset higher cat losses and less favorable prior-year development. Similarly, insurance margins beat (CR 92.6% vs. 94.3%E), while premiums missed (+7% vs. +8%E). Unlike peers, ACGL noted insignificant adverse development on casualty business in both the reinsurance and insurance divisions. MI margins were better than assumed as well (CR 7.2% vs. 20.9%E), helped by reserve releases on recent years. As assumed, Arch did not repurchase stock in 2Q. Management's tone on business trends was very upbeat, especially on pricing in the reinsurance market and margins in MI. A shortfall in insurance and MI premiums was the only major negative.
- **We forecast ACGL to report robust results in the near term, but our long-term outlook is more muted.** In our view, ACGL will report strong margins and top-line growth in re/insurance, and strong margins but lackluster growth in mortgage insurance. Reinsurance margins should benefit from hard pricing. MI margins should be lifted by elevated house prices and the strong labor market. Also, higher interest rates should boost premium persistency and margins, but are likely to suppress growth in the MI division. Meanwhile, we assume no share repurchases in the near term given ACGL's stock price and management's intent to deploy capital into the business amid the favorable pricing backdrop. On a cautious note, we do not expect margins in both the reinsurance and MI divisions to sustain at recent levels in the long run and remain wary of softening terms/conditions in the reinsurance market over time.
- **We maintain our Neutral rating.** We view ACGL as a top-tier franchise, but in commoditized markets. Hard reinsurance pricing should enable Arch to report robust results in the near term, but our long-term outlook for the reinsurance market is cautious. Furthermore, we feel that ACGL's valuation is not attractive given its long-term ROE and EPS growth potential.

### Neutral

**ACGL, ACGL US**  
Price (30 Jul 24): \$98.20

▲ **Price Target (Dec-25): \$108.00**  
Prior (Dec-25): \$106.00

### Insurance - Life & Nonlife

**Jimmy S. Bhullar, CFA** <sup>AC</sup>  
(1-212) 622-6397  
jimmy.s.bhullar@jpmorgan.com

**Pablo S. Singzon**  
(1-212) 622-2295  
pablo.s.singzon@jpmorgan.com

**Kevin Wijendra**  
(1-212) 622-7054  
kevin.wijendra@jpmorgan.com  
J.P. Morgan Securities LLC

### Key Changes (FYE Dec)

	Prev	Cur
Adj. EPS - 24E (\$)	8.53	9.13

### Quarterly Forecasts (FYE Dec)

Adj. EPS (\$)	2023A	2024E	2025E
Q1	1.73	2.45A	
Q2	1.92	2.57A	
Q3	2.31	1.76	
Q4	2.49	2.35	
FY	8.45	9.13	8.83

### Style Exposure

Quant Factors	Current %Rank	Hist %Rank (1=Top)				
		6M	1Y	3Y	5Y	
Value	100	100	100	100	100	
Growth	1	100	51	100	1	
Momentum	1	1	1	51	100	
Quality	51	1	1	100	1	
Low Vol	1	1	1	51	1	
ESGQ	12	12	13	91	98	

**2Q24 EPS: \$2.57A vs. \$2.05E**

**Positives:** underwriting margins in all divisions, reinsurance premium growth, investment income

**Negatives:** insurance and MI premiums

Sources for: Style Exposure – J.P. Morgan Quantitative and Derivatives Strategy; all other tables are company data and J.P. Morgan estimates.

### See page 14 for analyst certification and important disclosures.

J.P. Morgan does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

### Price Performance



### Summary Investment Thesis and Valuation

We affirm our Neutral rating. Arch is a leading reinsurance franchise with a track record of higher and less volatile underwriting margins than most peers. Hard pricing and tighter terms/conditions should boost underwriting results in the reinsurance business in the near term. Meanwhile, near-term results in the MI business should benefit from low attritional losses and reserve releases. On the other hand, our long-term outlook for the reinsurance market is cautious. This, along with current valuation, keep us Neutral on ACGL.

### Company Data


	YTD	1m	3m	12m
Abs	32.2%	-2.7%	5.0%	27.1%
Rel	17.7%	-2.7%	-3.5%	8.1%

Shares O/S (mn) 376  
52-week range (\$) 103.79-72.85  
Market cap (\$ mn) 36,923.20  
Exchange rate 1.00  
Free float(%) 96.6%  
3M - Avg daily vol (mn) 1.62  
3M - Avg daily val (\$ mn) 161.0  
Volatility (90 Day) 21  
Index S&P 500  
BBG BUY|HOLD|SELL 12|4|1

### Key Metrics (FYE Dec)

\$ in millions	FY23A	FY24E	FY25E	FY26E
<b>Financial Estimates</b>				
NEP (Premium)	12,440	14,513	16,786	18,300
Underwriting income	2,612	2,826	2,899	2,985
Net investment income	1,023	1,501	1,889	2,139
Operating income	3,635	4,326	4,788	5,125
Adj. PBT	3,569	4,668	4,681	5,020
Adj. net income	3,201	3,711	3,827	4,109
Adj. EPS	8.45	9.13	8.83	9.62
BBG EPS	7.96	8.55	8.86	9.24
DPS	0.00	0.00	0.00	0.00
Investments	16,792	20,963	23,902	27,130
BVPS	46.94	57.53	66.33	76.03
NAVPS	46.94	57.53	66.33	76.03
<b>Margins and Growth</b>				
Adj. EPS growth	73.4%	8.0%	(3.3%)	8.9%
<b>Ratios</b>				
Adj. tax rate	24.5%	8.7%	15.0%	15.0%
Loss ratio	(50.2%)	(52.2%)	(53.8%)	(54.7%)
Combined ratio	(21.4%)	(23.9%)	(24.9%)	(25.7%)
Invest inc. % of Investments	-	-	-	-
Regulatory solvency ratio	-	-	-	-
Leverage (Debt/Debt+Equity)	-	-	-	-
ROE	21.6%	18.9%	16.5%	15.7%
<b>Valuation</b>				
Dividend yield	0.0%	0.0%	0.0%	0.0%
Adj. P/E	11.6	10.8	11.1	10.2
P/BV	2.1	1.7	1.5	1.3

### Performance Drivers



Factors	6M Corr	1Y Corr
Market: MSCI EM Latam	0.09	-0.03
Country: Bermuda	-0.07	-0.22
<b>Macro:</b>		
Emerging Central Bank Rate	0.30	0.21
HSI Volatility Index	-0.03	-0.19
JPM China A-shares Sentiment	0.18	0.16
<b>Quant Styles:</b>		
Momentum	0.24	0.29
Quality	0.27	0.23
Value	0.39	0.23

Source: J.P. Morgan Quantitative and Derivatives Strategy for Performance Drivers; company data, Bloomberg Finance L.P. and J.P. Morgan estimates for all other tables. Note: Price history may not be complete or exact.

## Table Of Contents

---

<b>Investment Thesis.....</b>	<b>4</b>
P&C Reinsurance: Near-Term Outlook Upbeat; L-T Cautious.....	4
MI: Margins to Normalize Lower, Growth Modest .....	4
<b>2Q24 Details.....</b>	<b>5</b>
Mortgage Ins.: Healthy Margins Drove Earnings Upside.....	6
Insurance: Healthy Margins Offset Lower Premiums .....	8
Reinsurance: Strong Results Overall .....	9
<b>Raising EPS Estimates .....</b>	<b>10</b>

## Investment Thesis

**Please see Page 5 for a detailed review of 2Q24 results.** ACGL will hold its earnings conference call at 11:00 AM Eastern on July 31, 2024. Conference call participants need to register at this link: [edge.media-server.com/mmc/p/520jwcq3/](https://edge.media-server.com/mmc/p/520jwcq3/). The call replay can be accessed at: [ir.archcapgroup.com](http://ir.archcapgroup.com).

**We are Neutral on ACGL due to bullish sentiment and valuation, but consider it the best stock for investors seeking exposure to the firm reinsurance market.** ACGL is an industry-leading reinsurance franchise with a unique culture and approach to underwriting that should generate above-average, and less volatile, margins over time. The company is also a leading mortgage insurer, a business that we believe is structurally better than P&C reinsurance. In primary P&C, Arch has expanded its position in wholesale/E&S through the current hard market, and its pending acquisition of the Allianz book should bolster its middle market franchise. Our near-term outlook is upbeat as we expect Arch's results to benefit from firm prices and tight terms/conditions in re/insurance, and ongoing reserve releases in mortgage insurance. However, our long-term view is more muted, particularly for reinsurance, as we anticipate a softening of the pricing cycle if underwriting margins stay close to recent levels for the next 1-2 years. The reinsurance market suffers from structural issues such as low barriers to entry, lack of differentiation among carriers, and limited pricing power, all of which suggest more competition if margins stay elevated. Moreover, investor sentiment on ACGL seems very bullish, and we think that the stock's valuation already reflects optimism for near-term results. Still, our fundamental outlook for the company is constructive, and we could get more bullish on the stock if it pulls back.

### P&C Reinsurance: Near-Term Outlook Upbeat; L-T Cautious

**Reinsurance margins should benefit from hard pricing and tighter terms, but our long-term outlook remains downbeat.** ACGL has historically generated better and less volatile margins than most reinsurers because of its focus on specialty business (where pricing is less competitive), conservative underwriting, ability to shift mix with changing conditions, and judicious management of catastrophe risk. Also, ACGL prices business using the risk-free rate (leading to more conservative pricing), deploys a long-term compensation plan for underwriters based on margins over multiple years, and supplements re/insurance underwriting earnings with fee income from 3<sup>rd</sup> party capital vehicles such as Premia. Still, our long-term outlook for reinsurance remains cautious because of its commoditized nature, the ease of entry of new capital, and a broad set of capital providers (including some, such as pension funds, with lower return thresholds). We are skeptical of prolonged hard pricing and believe that 1-2 years of strong margins will erode pricing discipline. As such, barring an above-average hurricane season, we expect pricing momentum to slow, especially in higher layers of reinsurance programs, which are attracting more capital. Any signs of softening of terms/conditions or new capacity will likely hurt sentiment on reinsurance stocks, which are consensus longs.

### MI: Margins to Normalize Lower, Growth Modest

ACGL expanded in mortgage insurance via acquisitions (CMG in 2014 and United Guaranty in 2016) when market conditions were favorable, marked by rising home prices, stringent lending standards, and disciplined pricing by MI carriers. Arch's MI business has generated healthy margins since then and, despite the temporary setback from COVID-related delinquencies in 2020, results have been strong. Over the next few years, however, we expect MI margins to revert lower to more normal levels as reserve releases taper off. Still, ACGL's conservative loss picks post-COVID, the strong labor market, and appreciation of house prices are near-term positives for margins. Higher interest rates will suppress new sales, but should boost persistency in the business.

## 2Q24 Details

This evening, ACGL announced second quarter 2024 operating EPS of \$2.57, well above our \$2.05 estimate and consensus of \$2.18. Compared with our model, earnings beat in all three divisions, helped by robust margins. Reinsurance results were marked by higher than assumed margins (CR 79.5% vs. our 84.7% estimate) and premiums (+14% versus our -3% estimate). Margins benefited from lower attritional losses, which more than offset higher cat losses and less favorable prior-year development. Similarly, margins beat in both the insurance (CR 92.6% vs. 94.3%E) and MI divisions (CR 7.2% vs. 20.9%E). As anticipated, Arch did not repurchase stock in the second quarter. A shortfall in insurance and MI premiums was the only major negative.

**Table 1: 2Q24 Operating Earnings: Actual versus Expected**

\$ in millions, except per share amounts

	2Q24E	2Q24A	Upside / (downside) to EPS	Comments
<b>Underwriting Income by Division:</b>				
Mortgage	217	287	\$0.18	net written premiums +4.2% vs. +5.0%E; combined ratio 7.4% vs. 20.9%E
Insurance	86	109	\$0.06	net written premiums +7.2% vs. +8.2%E; combined ratio 92.6% vs. 94.3%E
Reinsurance	268	366	\$0.26	net written premiums +13.9% vs. -3.1%E; combined ratio 79.5% vs. 84.7%E
<b>Underwriting income</b>	<b>571</b>	<b>762</b>	<b>\$0.50</b>	net written premiums +10.3% vs. +2.3%E; combined ratio 78.7% vs. 83.9%E
Net investment income	345	364	\$0.05	pre-tax investment yield of 4.39% in 2Q24 versus 4.14% in 1Q24 and 3.50% in 3Q23
Earnings from affiliates	50	45	-\$0.01	
Other income (losses) / COLI	1	26	\$0.07	
Other expenses / corporate	51	68	-\$0.04	
Interest expense	35	35	\$0.00	
<b>Pretax operating income</b>	<b>881</b>	<b>1,094</b>	<b>\$0.56</b>	
Income tax expense	88	103	-\$0.04	tax rate of 9.4% vs. 10.0%E
Preferred dividends	10	10	\$0.00	
<b>Operating income</b>	<b>783</b>	<b>981</b>	<b>\$0.52</b>	
Weighted average dilutive shares	381.8	381.6	\$0.00	no share buybacks as expected
<b>Operating EPS</b>	<b>\$2.05</b>	<b>\$2.57</b>	<b>\$0.52</b>	<b>no major unusual items</b>

Source: Company reports and J.P. Morgan estimates.

**Business trends were better than assumed overall.** By business driver, the upside to our model was driven primarily by better margins and a lower underlying loss ratio. In addition, results benefited from higher investment income (\$0.04 per share after taxes), more favorable prior-year development (+\$0.02), lower cat losses (+\$0.01 variance), and lower tax rate (+\$0.10 per share).

Table 2: 2Q24 Key Financial Metrics

\$ in millions

	2Q24E	2Q24A
Net premiums written	3,507	3,781
% change (y-o-y)	2.3%	10.3%
Net investment income	345	364
% change (y-o-y)	42.5%	50.4%
Loss ratio ex cats and PYD	53.2%	49.2%
Catastrophe losses	5.6%	5.5%
PYD (favorable) / unfavorable	-3.3%	-3.5%
Loss ratio	55.5%	51.2%
Expense ratio	28.4%	27.5%
Combined ratio	83.9%	78.7%
Combined ratio ex cats & PYD	81.6%	76.7%
Share buybacks (\$ mil.)	-	-

Source: Company reports and J.P. Morgan estimates.

## Mortgage Ins.: Healthy Margins Drove Earnings Upside

**In our view, the mortgage insurance (MI) business will report modest gross premium growth, high persistency, and robust (albeit normalizing) margins.** High interest rates are a headwind for mortgage insurance volumes and reserve releases should moderate over time. Still, MI results have been significantly above expectations in recent periods, and we believe that there is a greater chance of upside to our prospective forecasts than downside. Also, net premium growth should benefit from higher retention following the cancellation of the Bellemeade transactions. A decline in rates would be a positive for new business volumes as well.

In 2Q24, the MI business reported underwriting income of \$287 million, well above our \$217 million estimate, driven by better margins (CR 7.4% vs. 20.9%E) and higher earned premium growth (+4.4% vs. -8.4%E). The upside in margins resulted from higher reserve releases (-29.0% vs. -20.5%E), a lower attritional loss ratio (20.4% vs. 24.0%E), and a lower expense ratio (16.0% vs. 17.4%E). As in 1Q24, the company attributed the reserve releases to favorable cure rates and the lower attritional losses to modest claims, partially offset by higher delinquencies. Gross premium growth in the MI market was sluggish (11th consecutive quarter of decline), but net written and net earned premium growth benefited from the termination of the Bellemeade agreements in 4Q23. We expect the factors boosting margins in the MI business (higher rates, lower inventory of houses, etc.) to continue suppressing gross premium growth.

In 2020 and early 2021, MI margins were hurt by artificially high delinquencies caused by homeowners availing themselves of government forbearance programs. However,

after an initial spike in 2Q20, the number of delinquent loans has been steadily declining. Following the expiry of forbearance programs, a significant portion of previously delinquent loans has cured, particularly loans by borrowers who were taking advantage of the mortgage payment holiday but were not in financial distress. In the meantime, higher house prices have provided a cushion to homeowners under stress who are struggling to pay their mortgages, limiting losses for MI carriers. The percent of loans in default in the U.S. primary MI business was 1.82% at 6/30/2024, up from 1.65% at 3/31/2024 and lower than 1.61% at 6/30/24.

**Table 3: Mortgage Insurance Key Metrics**

\$ in millions

	2Q22	3Q22	4Q22	2022	1Q23	2Q23	3Q23	4Q23	2023	1Q24	2Q24E	2Q24A
Net written premiums	294	276	275	1,133	261	265	271	255	1,052	277	278	276
Premium Growth (y/y)	-12.5%	-8.2%	-5.1%	-10.2%	-9.4%	-9.8%	-1.9%	-7.1%	-7.1%	6.1%	5.0%	4.2%
Losses and LAE ex. cats and PYD	18.8%	21.0%	25.2%	20.7%	25.3%	24.3%	21.6%	18.3%	22.4%	22.7%	24.0%	20.2%
Catastrophe losses	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
PYD (favorable) / unfavorable	-40.7%	-45.1%	-72.1%	-48.6%	-24.6%	-28.7%	-33.5%	-39.0%	-31.3%	-25.7%	-20.5%	-29.0%
Loss ratio	-21.9%	-24.1%	-46.9%	-28.0%	0.7%	-4.4%	-11.9%	-20.7%	-8.9%	-3.0%	3.5%	-8.8%
Acquisition expense ratio	3.4%	2.4%	4.4%	3.5%	2.4%	2.4%	0.7%	0.4%	1.5%	0.0%	0.4%	0.0%
Operating expense ratio	17.0%	16.5%	15.4%	16.8%	16.9%	17.0%	16.0%	17.1%	16.8%	17.4%	17.0%	16.0%
Expense ratio	20.4%	18.8%	19.8%	20.3%	19.3%	19.4%	16.7%	17.5%	18.2%	17.4%	17.4%	16.0%
Combined ratio	-1.5%	-5.2%	-27.1%	-7.7%	19.9%	15.0%	4.8%	-3.3%	9.3%	14.4%	20.9%	7.2%
Combined ratio ex cats & PYD	39.2%	39.9%	45.0%	41.0%	44.5%	43.7%	38.3%	35.7%	40.6%	40.1%	41.4%	36.2%
<b>Underwriting Income (Loss)</b>	<b>298</b>	<b>299</b>	<b>374</b>	<b>1,257</b>	<b>243</b>	<b>253</b>	<b>282</b>	<b>286</b>	<b>1,064</b>	<b>271</b>	<b>217</b>	<b>287</b>

Source: Company reports and J.P. Morgan estimates.

**Reserve releases should continue to lift MI margins, but to a lesser extent than in prior quarters.** Higher reported delinquencies at the onset of COVID led Arch and its MI peers to establish corresponding reserves despite the healthy labor market and appreciation in house prices. A meaningful portion of these delinquencies was due to homeowners taking advantage of the government's forbearance protection programs (to preserve liquidity), not actual financial hardship, so actual losses were well below those suggested by initial delinquencies. In recent quarters, over 80% of MI reserves are from accident years after COVID, suggesting less of a benefit from the release of reserves related to COVID delinquencies. Even with this expected decline, however, we expect MI margins to remain healthy given the strong labor and housing markets, cures on previously delinquent loans, and the equity cushion accumulated by homeowners due to the appreciation in house prices. Higher interest rates are a positive for margins as well as they are causing homeowners to stay longer in their existing houses (where they have more equity), thereby improving persistency in the MI book. On a cautious note, top-line growth in the MI business is likely to be weak as higher interest rates reduce mortgage originations. Although a weaker economy could deflate home prices and lead to higher mortgage defaults, a material uptick in losses seems unlikely in the near term. Barring a recession, we expect core margins to stay healthy, though declining reserve releases will drive margins and earnings lower even if economic trends stay favorable.

**ACGL has become a leading competitor in the MI market through acquisitions and could expand further via M&A, although deals seem unlikely in the near term.**  
 ACGL entered the mortgage re/insurance business in 2011 but was only marginally

involved in the market at the onset, competing as a primary insurer through credit unions and as a reinsurer through the GSE credit risk transfer program. The company's 2014 acquisition of CMG Mortgage Insurance from Cuna Mutual gave it a bigger foothold as it received a ratings upgrade for its MI business (from BBB+ to A- at S&P) and gained distribution in the bank channel. Following the deal, Arch became a top 10 competitor in the domestic private MI market. Arch's market position strengthened further following its 2017 acquisition of United Guaranty (UGC) from AIG, which catapulted it to a top-3 spot (as part of the deal AIG retained 50% of mortgage insurance blocks originated by UGC pre 2017). Arch has also expanded in foreign MI markets through M&A, including its acquisition of Westpac's mortgage insurance business in Australia (closed in August 2021).

### Insurance: Healthy Margins Offset Lower Premiums

**ACGL's insurance business reported modestly weaker premium growth, but better than expected underwriting margins, helped by lower catastrophe losses.**

Underwriting income in 2Q24 was \$109 million, better than our \$86 million estimate. Margins were stronger than assumed on a reported basis (CR 92.6% vs. 94.3%E), but worse on a core basis (CR ex. cats and PYD 90.8% vs. 89.6%E). Lower catastrophe losses (2.0% vs. 5.0%E) more than offset slightly worse attritional losses (55.6% vs. 55.5%E), lower reserve releases (-0.2% vs. -0.3%E), and higher expenses (35.3% vs. 34.1%E). Gross written premium growth (+7.5% vs. +8.0%E), net written premium growth (+7.2% vs. +8.2%E), and net earned premium growth (+11.3% vs. +13.6%E) were slightly softer.

**Table 4: Insurance Key Metrics**

\$ in millions

	2Q22	3Q22	4Q22	2022	1Q23	2Q23	3Q23	4Q23	2023	1Q24	2Q24E	2Q24A
Net written premiums	1,228	1,369	1,217	5,021	1,437	1,454	1,522	1,449	5,862	1,542	1,573	1,558
Premium Growth (y/y)	27.5%	18.6%	17.4%	21.0%	19.1%	18.4%	11.2%	19.1%	16.8%	7.3%	8.2%	7.2%
Losses and LAE ex. cats and PYD	56.0%	56.0%	56.2%	56.0%	54.8%	55.2%	55.7%	55.1%	55.2%	57.5%	55.5%	55.6%
Catastrophe losses	1.5%	13.4%	2.8%	5.3%	1.6%	2.6%	2.6%	3.8%	2.7%	1.9%	5.0%	2.0%
PYD (favorable) / unfavorable	-0.4%	-0.1%	-0.3%	-0.2%	-0.5%	-0.5%	-0.8%	-0.5%	-0.6%	-0.5%	-0.3%	-0.2%
Loss ratio	57.1%	69.3%	58.7%	61.0%	55.9%	57.3%	57.5%	58.4%	57.3%	58.9%	60.2%	57.4%
Acquisition expense ratio	19.4%	19.6%	19.6%	19.4%	19.5%	19.9%	19.1%	19.1%	19.4%	19.0%	19.1%	19.5%
Operating expense ratio	14.6%	13.9%	13.8%	14.6%	15.5%	14.7%	14.3%	15.7%	15.0%	16.2%	15.0%	15.8%
Expense ratio	34.0%	33.5%	33.5%	34.0%	35.0%	34.6%	33.4%	34.8%	34.4%	35.2%	34.1%	35.3%
Combined ratio	91.1%	102.8%	92.1%	95.1%	90.9%	91.9%	90.9%	93.2%	91.7%	94.1%	94.3%	92.6%
Combined ratio ex cats & PYD	90.0%	89.5%	89.6%	90.0%	89.8%	89.8%	89.1%	89.9%	89.6%	92.7%	89.6%	90.8%
Underwriting Income (Loss)	98	(34)	98	225	114	108	129	99	450	86	86	109

Source: Company reports and J.P. Morgan estimates.

**Arch's primary P&C business is benefiting from favorable pricing, but we do not expect further margin expansion from current levels.** After shrinking its "cycle managed" business (now called as wholesale/large capacity) from 2012 to 2017, ACGL is seeing strong growth in this part of its primary book, driven by price hikes in the broader market, particularly in E&S. Results in less opportunistic parts of ACGL's book

(specialty small/middle market and franchise) have been healthy as well. High inflation and rising reinsurance costs are driving an uptick in insurance pricing, especially in property and cat-exposed lines. Despite firm pricing, we do not anticipate a material improvement in primary commercial lines margins at Arch and peers because of headwinds from higher inflation and reinsurance costs. Also, reserve development could become less of a tailwind because of adverse loss trends emerging in older accident years. Management teams at insurance underwriters as well as many investors are optimistic about improving non-cat margins at commercial insurers, but **we feel that assessing results on a non-cat basis is not as relevant given the significant increase in reinsurance retentions at primary companies.** On an overall combined ratio basis, results for most primary insurers were weak in 2023, precisely because of elevated cat losses. In contrast, reinsurers' cat losses have not increased to the same extent. In our opinion, consensus EPS forecasts for commercial lines insurers do not adequately reflect the shift in cat loads from reinsurers to primary carriers following the uptick in retention levels with 2023 reinsurance renewals.

## Reinsurance: Strong Results Overall

**Reinsurance results were marked by upside in margins and premium growth.** The business generated underwriting income of \$366 million in 2Q24, well above our \$268 million estimate, driven by stronger premium growth and better margins (CR 79.5% vs. 84.7%E, CR ex. cats and PYD 71.9% vs. 80.9%E). Catastrophe losses (9.4% vs. 7.0%E) and lower reserve releases (-1.8% vs. -2.0%E) were unfavorable to our model, but were more than offset by lower attritional losses (48.9% vs. 55.7%E) and expenses (23.0% vs. 25.2%E). Premium growth was healthy (gross written premiums +15.6% vs. +1.7%E, net written premiums +13.9% vs. -3.1%E, net earned premiums +32.5% vs. 30.3%E). Management was upbeat on Arch's positioning in the property cat market despite pricing moderation from last year. The increase in reinsurance attachment points in early 2023 shifted the risk of cat losses from reinsurers to primary carriers, and management indicated that terms remain consistent.

**Table 5: Reinsurance Key Metrics**

\$ in millions

	2Q22	3Q22	4Q22	2022	1Q23	2Q23	3Q23	4Q23	2023	1Q24	2Q24E	2Q24A
Net written premiums	1,163	1,079	1,543	4,924	1,726	1,709	1,582	1,557	6,554	2,266	1,656	1,947
Premium Growth (y/y)	25.7%	73.6%	117.6%	51.3%	51.5%	47.0%	44.8%	0.9%	33.1%	31.3%	-3.1%	13.9%
Losses and LAE ex. cats and PYD	55.3%	58.4%	57.4%	56.2%	56.6%	50.8%	49.9%	48.5%	51.3%	53.7%	55.7%	48.9%
Catastrophe losses	7.1%	39.1%	0.0%	12.9%	4.4%	6.3%	9.3%	5.1%	6.3%	1.8%	7.0%	9.4%
PYD (favorable) / unfavorable	-4.5%	-4.9%	-4.5%	-4.3%	-3.4%	-1.8%	-2.8%	-1.3%	-2.3%	-2.5%	-3.2%	-1.8%
Loss ratio	57.9%	92.6%	52.9%	64.9%	57.6%	55.3%	56.4%	52.3%	55.3%	53.0%	59.5%	56.5%
Acquisition expense ratio	20.4%	20.8%	19.9%	20.5%	21.1%	21.6%	19.7%	22.5%	21.2%	19.9%	21.0%	19.4%
Operating expense ratio	7.1%	6.3%	5.6%	6.8%	5.6%	5.1%	4.0%	5.2%	4.9%	4.5%	4.2%	3.6%
Expense ratio	27.5%	27.1%	25.5%	27.3%	26.7%	26.7%	23.7%	27.8%	26.2%	24.4%	25.2%	23.0%
Combined ratio	85.5%	119.7%	78.5%	92.2%	84.3%	82.0%	80.0%	80.1%	81.5%	77.4%	84.7%	79.5%
Combined ratio ex cats & PYD	82.9%	85.5%	83.0%	83.5%	83.3%	77.5%	73.5%	76.3%	77.4%	78.1%	80.9%	71.9%
Underwriting Income (Loss)	139	(197)	263	314	213	245	310	330	1,098	379	268	366

Source: Company reports and J.P. Morgan estimates.

**We are skeptical of a prolonged hard market, but trends are holding up better than expected and ACGL seems better positioned than peers in this environment.**

ACGL's reinsurance segment was initially established to take advantage of the hard market for casualty coverage in the early 2000s. Over the years, however, management has shifted Arch Re's business mix away from casualty risks towards other specialty lines such as surety, accident and health, agriculture, and trade credit, which are generally less competitive and have more attractive risk-reward. The hard pricing environment has boosted results in recent years and is causing management to increase its exposure to property coverages. This, in turn, should drive continued strong premiums and margins. Longer term, however, we remain skeptical of a sustained hard reinsurance market and expect the pace of price hikes to moderate. Factors that contributed to a multi-year soft market prior to 2018 (glut of capital, greater fluidity/speed of capital, more providers of capacity, broker consolidation) are still prevalent, and should preclude prolonged hard pricing. On a positive note, ACGL's reinsurance results could benefit from the release of COVID-related reserves, a portion of which remain in IBNR. Similarly, loss reserves for Ian and other cat events could ultimately prove to be too conservative.

## Raising EPS Estimates

**We are raising 3Q24 EPS from \$1.72 to \$1.76 and 2025 EPS from \$8.63 to \$8.83.**  
Our 2024 EPS estimate is increasing as well, from \$8.53 to \$9.13. Our revised model reflects higher run-rate investment income. We did not materially alter our assumptions for premiums or margins, but feel that underwriting income is more likely to exceed than miss our assumptions. We consider catastrophe losses (which would affect reinsurance and insurance margins) and housing market conditions (which affect MI margins and premium growth) the key sources of potential variance in reported results and our projections.

## Arch Capital (Neutral; Price Target: \$108.00)

### Investment Thesis

We view Arch as a premier re/insurance franchise, but bullish investor sentiment and valuation keep us from being more positive on the stock. Arch is a leading reinsurance business that we project to report superior and less volatile underwriting margins over time given its unique culture and approach to the market. Also, Arch is a top competitor in mortgage insurance (MI), which we consider a structurally better business than P&C reinsurance. In the near term, we expect MI results to be marked by improving premium growth and healthy margins, with reserve releases more than offsetting higher attritional losses. In reinsurance, firm pricing should boost both premium growth and margins as well. However, our long-term outlook for the reinsurance business is downbeat. We believe that structural issues such as low barriers to entry, lack of differentiation by carrier, and limited pricing power will drive a softening of reinsurance prices if margins stay close to recent levels over the next 1-2 years. Also, investor sentiment on ACGL is bullish and the stock's valuation does not seem compelling relative to the company's long-term ROE and EPS growth potential.

### Valuation

We are raising our December 2025 price target from \$106 to \$108 to reflect our higher EPS and book value estimates. Our price target assumes a 1.7x multiple on our 12/31/25E BV ex. AOCI forecast, a 1.7x multiple on our 12/31/25E BV forecast, and an 11.0x multiple on our 2026 EPS estimate, and we corroborate this approach with a sum-of-the-parts analysis that values ACGL's re/insurance business separately from mortgage insurance. Our target multiples for ACGL reflect its current business mix, which has become less skewed to MI. ACGL trades at 2.0x BV and 11.1x 2025E EPS compared to 1.4x and 7.7x for the reinsurance sector, 1.2x and 9.0x for MI peers, and 2.0x and 11.7x for the broader P&C group.

### Risks to Rating and Price Target

In our opinion, ACGL could outperform and exceed our price target if:

- **Re/insurance pricing stays firm for a prolonged period.** A prolonged hard market could drive upside to our EPS estimates and lift sentiment on the stock.
- **Management sustains insurance underwriting margins close to the recent level.** In our view, investor sentiment could improve if ACGL is able to sustain insurance combined ratios in the low to mid 90s, a significant improvement from ~100% previously, even as the tailwind from the current hard market recedes.
- **The company announces a sizable share repurchase program.** Steady repurchases by leading reinsurers could help prolong the hard market as well as drive an uptick in EPS forecasts.

We feel that the stock could underperform the group and fail to reach our target if:

- **Additional capacity enters the reinsurance market.** This, in turn, could result in a reversal in pricing trends and potentially drive a reduction in EPS estimates as well as hurt sentiment on the sector.
- **The housing market deteriorates.** Given Arch's meaningful exposure to mortgage insurance and the more systematic nature of mortgage insurance risk, rising unemployment, higher mortgage defaults, and decreasing home values would pressure the company's results and hurt sentiment on the stock.

- **The pace of reserve development moderates.** Favorable reserve development has been a notable contributor to ACGL's results in recent years. A slowdown in the pace of development could pressure margins and returns.

## Arch Capital: Summary of Financials

Income Statement - Annual	FY23A	FY24E	FY25E	Income Statement - Quarterly	1Q24A	2Q24A	3Q24E	4Q24E
Earned premiums	-	-	-	Earned premiums	-	-	-	-
Policy charges and fee income	-	-	-	Policy charges and fee income	-	-	-	-
Net investment income	-	-	-	Net investment income	-	-	-	-
Other income	-	-	-	Other income	-	-	-	-
<b>Total revenues</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>Total revenues</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
Insurance and annuity benefits	-	-	-	Insurance and annuity benefits	-	-	-	-
Interest credited	-	-	-	Interest credited	-	-	-	-
Interest expense	(133)	(140)	(146)	Interest expense	(34)A	(35)A	(35)	(36)
Acquisition & operating expenses	(2,312)	(2,660)	(3,178)	Acquisition & operating expenses	(607)A	(633)A	(689)	(731)
Amortization of acquisition costs (net)	-	-	-	Amortization of acquisition costs (net)	-	-	-	-
Other expenses	-	-	-	Other expenses	-	-	-	-
<b>Total expenses</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>Total expenses</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
Pretax income	3,569	4,668	4,681	Pretax income	1,221A	1,366A	903	1,179
Income taxes	873	(406)	(702)	Income taxes	(101)A	(97)A	(90)	(118)
Total net income	4,403	4,222	3,939	Total net income	1,110A	1,259A	803	1,051
Total operating income	3,201	3,711	3,827	Total operating income	933A	981A	774	1,022
Weighted average diluted shares	379	406	433	Weighted average diluted shares	381A	382A	440	435
<b>EPS - operating</b>	<b>8.45</b>	<b>9.13</b>	<b>8.83</b>	<b>EPS - operating</b>	<b>2.45A</b>	<b>2.57A</b>	<b>1.76</b>	<b>2.35</b>
Balance Sheet and Capital Data	FY23A	FY24E	FY25E	Ratio Analysis	FY23A	FY24E	FY25E	FY26E
Shareholders' equity	-	-	-	EPS growth - operating	73.4%	8.0%	(3.3%)	8.9%
Shareholders' equity ex. AOCI	-	-	-	Book value per share (ex. AOCI) growth	31.5%	22.4%	14.8%	14.2%
Shares outstanding	373	377	371	Return on equity (ROE)	21.6%	18.9%	16.5%	15.7%
Book value per share	46.94	57.53	66.33	Return on equity (ex. AOCI)	-	-	-	-
Book value per share (ex. AOCI)	48.75	59.68	68.51	Dividend payout ratio	0.0%	0.0%	0.0%	0.0%
Capital for share repurchases	-	-	-	Total revenue growth	-	-	-	-
Capital for dividends	-	-	-	Total expense growth	-	-	-	-
Dividends	0.00	0.00	0.00	Tax rate	24.5%	8.7%	15.0%	15.0%

Source: Company reports and J.P. Morgan estimates.  
 Note: \$ in millions (except per-share data). Fiscal year ends Dec

**Analyst Certification:** The Research Analyst(s) denoted by an “AC” on the cover of this report certifies (or, where multiple Research Analysts are primarily responsible for this report, the Research Analyst denoted by an “AC” on the cover or within the document individually certifies, with respect to each security or issuer that the Research Analyst covers in this research) that: (1) all of the views expressed in this report accurately reflect the Research Analyst’s personal views about any and all of the subject securities or issuers; and (2) no part of any of the Research Analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the Research Analyst(s) in this report. For all Korea-based Research Analysts listed on the front cover, if applicable, they also certify, as per KOFIA requirements, that the Research Analyst’s analysis was made in good faith and that the views reflect the Research Analyst’s own opinion, without undue influence or intervention.

All authors named within this report are Research Analysts who produce independent research unless otherwise specified. In Europe, Sector Specialists (Sales and Trading) may be shown on this report as contacts but are not authors of the report or part of the Research Department.


## Important Disclosures

---

- **Market Maker:** J.P. Morgan Securities LLC makes a market in the securities of Arch Capital.
- **Market Maker/ Liquidity Provider:** J.P. Morgan is a market maker and/or liquidity provider in the financial instruments of/related to Arch Capital.
- **Client:** J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as clients: Arch Capital.
- **Client/Non-Investment Banking, Securities-Related:** J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as clients, and the services provided were non-investment-banking, securities-related: Arch Capital.
- **Client/Non-Securities-Related:** J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as clients, and the services provided were non-securities-related: Arch Capital.
- **Non-Investment Banking Compensation Received:** J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Arch Capital.
- **Debt Position:** J.P. Morgan may hold a position in the debt securities of Arch Capital, if any.

**Company-Specific Disclosures:** Important disclosures, including price charts and credit opinion history tables, are available for compendium reports and all J.P. Morgan-covered companies, and certain non-covered companies, by visiting <https://www.jpmm.com/research/disclosures>, calling 1-800-477-0406, or e-mailing [research.disclosure.inquiries@jpmorgan.com](mailto:research.disclosure.inquiries@jpmorgan.com) with your request.

Arch Capital (ACGL, ACGL US) Price Chart



The chart(s) show J.P. Morgan's continuing coverage of the stocks; the current analysts may or may not have covered it over the entire period. J.P. Morgan ratings or designations: OW = Overweight, N= Neutral, UW = Underweight, NR = Not Rated

### Explanation of Equity Research Ratings, Designations and Analyst(s) Coverage Universe:

J.P. Morgan uses the following rating system: Overweight (over the duration of the price target indicated in this report, we expect this stock will outperform the average total return of the stocks in the Research Analyst’s, or the Research Analyst’s team’s, coverage universe); Neutral (over

the duration of the price target indicated in this report, we expect this stock will perform in line with the average total return of the stocks in the Research Analyst's, or the Research Analyst's team's, coverage universe); and Underweight (over the duration of the price target indicated in this report, we expect this stock will underperform the average total return of the stocks in the Research Analyst's, or the Research Analyst's team's, coverage universe. NR is Not Rated. In this case, J.P. Morgan has removed the rating and, if applicable, the price target, for this stock because of either a lack of a sufficient fundamental basis or for legal, regulatory or policy reasons. The previous rating and, if applicable, the price target, no longer should be relied upon. An NR designation is not a recommendation or a rating. In our Asia (ex-Australia and ex-India) and U.K. small- and mid-cap Equity Research, each stock's expected total return is compared to the expected total return of a benchmark country market index, not to those Research Analysts' coverage universe. If it does not appear in the Important Disclosures section of this report, the certifying Research Analyst's coverage universe can be found on J.P. Morgan's Research website, <https://www.jpmorganmarkets.com>.

**Coverage Universe:** **Bhullar, Jimmy S:** AFLAC, Inc. (AFL), Allstate (ALL), American International Group (AIG), Aon (AON), Arch Capital (ACGL), Brighthouse Financial (BHF), Chubb Ltd (CB), Corebridge Financial (CRBG), Equitable Holdings Inc (EQH), Globe Life Inc (GL), Hartford Financial Services (HIG), Lincoln National (LNC), Marsh & McLennan (MMC), MetLife, Inc. (MET), Principal Financial Group (PFG), Progressive (PGR), Prudential Financial (PRU), Reinsurance Group of America (RGA), RenaissanceRe (RNR), Ryan Specialty Group (RYAN), Travelers Cos (TRV), Unum Group (UNM), Voya Financial, Inc. (VOYA)

#### J.P. Morgan Equity Research Ratings Distribution, as of July 06, 2024

	Overweight (buy)	Neutral (hold)	Underweight (sell)
J.P. Morgan Global Equity Research Coverage*	49%	38%	13%
IB clients**	49%	46%	34%
JPMS Equity Research Coverage*	48%	41%	11%
IB clients**	69%	66%	50%

\*Please note that the percentages may not add to 100% because of rounding.

\*\*Percentage of subject companies within each of the "buy," "hold" and "sell" categories for which J.P. Morgan has provided investment banking services within the previous 12 months.

For purposes of FINRA ratings distribution rules only, our Overweight rating falls into a buy rating category; our Neutral rating falls into a hold rating category; and our Underweight rating falls into a sell rating category. Please note that stocks with an NR designation are not included in the table above. This information is current as of the end of the most recent calendar quarter.

**Equity Valuation and Risks:** For valuation methodology and risks associated with covered companies or price targets for covered companies, please see the most recent company-specific research report at <http://www.jpmorganmarkets.com>, contact the primary analyst or your J.P. Morgan representative, or email [research.disclosure.inquiries@jpmorgan.com](mailto:research.disclosure.inquiries@jpmorgan.com). For material information about the proprietary models used, please see the Summary of Financials in company-specific research reports and the Company Tearsheets, which are available to download on the company pages of our client website, <http://www.jpmorganmarkets.com>. This report also sets out within it the material underlying assumptions used.

A history of J.P. Morgan investment recommendations disseminated during the preceding 12 months can be accessed on the Research & Commentary page of <http://www.jpmorganmarkets.com> where you can also search by analyst name, sector or financial instrument.

**Analysts' Compensation:** The research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues.

#### Other Disclosures

J.P. Morgan is a marketing name for investment banking businesses of JPMorgan Chase & Co. and its subsidiaries and affiliates worldwide.

**UK MIFID FICC research unbundling exemption:** UK clients should refer to [UK MIFID Research Unbundling exemption](#) for details of J.P. Morgan's implementation of the FICC research exemption and guidance on relevant FICC research categorisation.

All research material made available to clients are simultaneously available on our client website, J.P. Morgan Markets, unless specifically permitted by relevant laws. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research material available on a particular stock, please contact your sales representative.

Any long form nomenclature for references to China; Hong Kong; Taiwan; and Macau within this research material are Mainland China; Hong Kong SAR (China); Taiwan (China); and Macau SAR (China).

J.P. Morgan Research may, from time to time, write on issuers or securities targeted by economic or financial sanctions imposed or administered by the governmental authorities of the U.S., EU, UK or other relevant jurisdictions (Sanctioned Securities). Nothing in this report is intended to be read or construed as encouraging, facilitating, promoting or otherwise approving investment or dealing in such Sanctioned Securities. Clients should be aware of their own legal and compliance obligations when making investment decisions.

Any digital or crypto assets discussed in this research report are subject to a rapidly changing regulatory landscape. For relevant regulatory

advisories on crypto assets, including bitcoin and ether, please see <https://www.jpmorgan.com/disclosures/cryptoasset-disclosure>.

The author(s) of this research report may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so.

**Exchange-Traded Funds (ETFs):** J.P. Morgan Securities LLC (“JPMS”) acts as authorized participant for substantially all U.S.-listed ETFs. To the extent that any ETFs are mentioned in this report, JPMS may earn commissions and transaction-based compensation in connection with the distribution of those ETF shares and may earn fees for performing other trade-related services, such as securities lending to short sellers of the ETF shares. JPMS may also perform services for the ETFs themselves, including acting as a broker or dealer to the ETFs. In addition, affiliates of JPMS may perform services for the ETFs, including trust, custodial, administration, lending, index calculation and/or maintenance and other services.

**Options and Futures related research:** If the information contained herein regards options- or futures-related research, such information is available only to persons who have received the proper options or futures risk disclosure documents. Please contact your J.P. Morgan Representative or visit <https://www.theocc.com/components/docs/riskstoc.pdf> for a copy of the Option Clearing Corporation's Characteristics and Risks of Standardized Options or [http://www.finra.org/sites/default/files/Security\\_Futures\\_Risk\\_Disclosure\\_Statement\\_2018.pdf](http://www.finra.org/sites/default/files/Security_Futures_Risk_Disclosure_Statement_2018.pdf) for a copy of the Security Futures Risk Disclosure Statement.

**Changes to Interbank Offered Rates (IBORs) and other benchmark rates:** Certain interest rate benchmarks are, or may in the future become, subject to ongoing international, national and other regulatory guidance, reform and proposals for reform. For more information, please consult: [https://www.jpmorgan.com/global/disclosures/interbank\\_offered\\_rates](https://www.jpmorgan.com/global/disclosures/interbank_offered_rates)

**Private Bank Clients:** Where you are receiving research as a client of the private banking businesses offered by JPMorgan Chase & Co. and its subsidiaries (“J.P. Morgan Private Bank”), research is provided to you by J.P. Morgan Private Bank and not by any other division of J.P. Morgan, including, but not limited to, the J.P. Morgan Corporate and Investment Bank and its Global Research division.

**Legal entity responsible for the production and distribution of research:** The legal entity identified below the name of the Reg AC Research Analyst who authored this material is the legal entity responsible for the production of this research. Where multiple Reg AC Research Analysts authored this material with different legal entities identified below their names, these legal entities are jointly responsible for the production of this research. Research Analysts from various J.P. Morgan affiliates may have contributed to the production of this material but may not be licensed to carry out regulated activities in your jurisdiction (and do not hold themselves out as being able to do so). Unless otherwise stated below, this material has been distributed by the legal entity responsible for production. If you have any queries, please contact the relevant Research Analyst in your jurisdiction or the entity in your jurisdiction that has distributed this research material.

**Legal Entities Disclosures and Country-/Region-Specific Disclosures:**

**Argentina:** JPMorgan Chase Bank N.A Sucursal Buenos Aires is regulated by Banco Central de la República Argentina (“BCRA”- Central Bank of Argentina) and Comisión Nacional de Valores (“CNV”- Argentinian Securities Commission - ALYC y AN Integral N°51). **Australia:** J.P. Morgan Securities Australia Limited (“JPMSAL”) (ABN 61 003 245 234/AFS Licence No: 238066) is regulated by the Australian Securities and Investments Commission and is a Market Participant of ASX Limited, a Clearing and Settlement Participant of ASX Clear Pty Limited and a Clearing Participant of ASX Clear (Futures) Pty Limited. This material is issued and distributed in Australia by or on behalf of JPMSAL only to “wholesale clients” (as defined in section 761G of the Corporations Act 2001). A list of all financial products covered can be found by visiting <https://www.jpmm.com/research/disclosures>. J.P. Morgan seeks to cover companies of relevance to the domestic and international investor base across all Global Industry Classification Standard (GICS) sectors, as well as across a range of market capitalisation sizes. If applicable, in the course of conducting public side due diligence on the subject company(ies), the Research Analyst team may at times perform such diligence through corporate engagements such as site visits, discussions with company representatives, management presentations, etc. Research issued by JPMSAL has been prepared in accordance with J.P. Morgan Australia’s Research Independence Policy which can be found at the following link: [J.P. Morgan Australia - Research Independence Policy](#). **Brazil:** Banco J.P. Morgan S.A. is regulated by the Comissão de Valores Mobiliários (CVM) and by the Central Bank of Brazil. Ombudsman J.P. Morgan: 0800-7700847 / 0800-7700810 (For Hearing Impaired) / [ouvidoria.jp.morgan@jpmorgan.com](mailto:ouvidoria.jp.morgan@jpmorgan.com). **Canada:** J.P. Morgan Securities Canada Inc. is a registered investment dealer, regulated by the Canadian Investment Regulatory Organization and the Ontario Securities Commission and is the participating member on Canadian exchanges. This material is distributed in Canada by or on behalf of J.P. Morgan Securities Canada Inc. **Chile:** Inversiones J.P. Morgan Limitada is an unregulated entity incorporated in Chile. **China:** J.P. Morgan Securities (China) Company Limited has been approved by CSRC to conduct the securities investment consultancy business. **Dubai International Financial Centre (DIFC):** JPMorgan Chase Bank, N.A., Dubai Branch is regulated by the Dubai Financial Services Authority (DFSA) and its registered address is Dubai International Financial Centre - The Gate, West Wing, Level 3 and 9 PO Box 506551, Dubai, UAE. This material has been distributed by J.P. Morgan Chase Bank, N.A., Dubai Branch to persons regarded as professional clients or market counterparties as defined under the DFSA rules. **European Economic Area (EEA):** Unless specified to the contrary, research is distributed in the EEA by J.P. Morgan SE (“JPM SE”), which is authorised as a credit institution by the Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB). JPM SE is a company headquartered in Frankfurt with registered address at TaunusTurm, Taunustor 1, Frankfurt am Main, 60310, Germany. The material has been distributed in the EEA to persons regarded as professional investors (or equivalent) pursuant to Art. 4 para. 1 no. 10 and Annex II of MiFID II and its respective implementation in their home jurisdictions (“EEA professional investors”). This material must not be acted on or relied on by persons who are not EEA professional investors. Any investment or investment activity to which this material relates is only available to EEA relevant persons and will be engaged in only with EEA relevant persons. **Hong Kong:** J.P. Morgan Securities (Asia Pacific) Limited (CE number AAJ321) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission in Hong Kong, and J.P. Morgan Broking (Hong

Kong) Limited (CE number AAB027) is regulated by the Securities and Futures Commission in Hong Kong. JP Morgan Chase Bank, N.A., Hong Kong Branch (CE Number AAL996) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission, is organized under the laws of the United States with limited liability. Where the distribution of this material is a regulated activity in Hong Kong, the material is distributed in Hong Kong by or through J.P. Morgan Securities (Asia Pacific) Limited and/or J.P. Morgan Broking (Hong Kong) Limited. **India:** J.P. Morgan India Private Limited (Corporate Identity Number - U67120MH1992FTC068724), having its registered office at J.P. Morgan Tower, Off. C.S.T. Road, Kalina, Santacruz - East, Mumbai – 400098, is registered with the Securities and Exchange Board of India (SEBI) as a ‘Research Analyst’ having registration number INH000001873. J.P. Morgan India Private Limited is also registered with SEBI as a member of the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited (SEBI Registration Number – INZ000239730) and as a Merchant Banker (SEBI Registration Number - MB/INM000002970). Telephone: 91-22-6157 3000, Facsimile: 91-22-6157 3990 and Website: <http://www.jpmipl.com>. JPMorgan Chase Bank, N.A. - Mumbai Branch is licensed by the Reserve Bank of India (RBI) (Licence No. 53/ Licence No. BY.4/94; SEBI - IN/CUS/014/ CDSL : IN-DP-CDSL-444-2008/ IN-DP-NSDL-285-2008/ INBI00000984/ INE231311239) as a Scheduled Commercial Bank in India, which is its primary license allowing it to carry on Banking business in India and other activities, which a Bank branch in India are permitted to undertake. For non-local research material, this material is not distributed in India by J.P. Morgan India Private Limited. Compliance Officer: Spurthi Gadamsetty; [spurthi.gadamsetty@jpmchase.com](mailto:spurthi.gadamsetty@jpmchase.com); +912261573225. Grievance Officer: Ramprasadh K, [jpmipl.research.feedback@jpmorgan.com](mailto:jpmipl.research.feedback@jpmorgan.com); +912261573000.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

**Indonesia:** PT J.P. Morgan Sekuritas Indonesia is a member of the Indonesia Stock Exchange and is registered and supervised by the Otoritas Jasa Keuangan (OJK). **Korea:** J.P. Morgan Securities (Far East) Limited, Seoul Branch, is a member of the Korea Exchange (KRX). JPMorgan Chase Bank, N.A., Seoul Branch, is licensed as a branch office of foreign bank (JPMorgan Chase Bank, N.A.) in Korea. Both entities are regulated by the Financial Services Commission (FSC) and the Financial Supervisory Service (FSS). For non-macro research material, the material is distributed in Korea by or through J.P. Morgan Securities (Far East) Limited, Seoul Branch. **Japan:** JPMorgan Securities Japan Co., Ltd. and JPMorgan Chase Bank, N.A., Tokyo Branch are regulated by the Financial Services Agency in Japan. **Malaysia:** This material is issued and distributed in Malaysia by JPMorgan Securities (Malaysia) Sdn Bhd (18146-X), which is a Participating Organization of Bursa Malaysia Berhad and holds a Capital Markets Services License issued by the Securities Commission in Malaysia. **Mexico:** J.P. Morgan Casa de Bolsa, S.A. de C.V. and J.P. Morgan Grupo Financiero are members of the Mexican Stock Exchange and are authorized to act as a broker dealer by the National Banking and Securities Exchange Commission. **New Zealand:** This material is issued and distributed by JPMSAL in New Zealand only to "wholesale clients" (as defined in the Financial Markets Conduct Act 2013). JPMSAL is registered as a Financial Service Provider under the Financial Service providers (Registration and Dispute Resolution) Act of 2008. **Philippines:** J.P. Morgan Securities Philippines Inc. is a Trading Participant of the Philippine Stock Exchange and a member of the Securities Clearing Corporation of the Philippines and the Securities Investor Protection Fund. It is regulated by the Securities and Exchange Commission. **Singapore:** This material is issued and distributed in Singapore by or through J.P. Morgan Securities Singapore Private Limited (JPMS) [MCI (P) 030/08/2023 and Co. Reg. No.: 199405335R], which is a member of the Singapore Exchange Securities Trading Limited, and/or JPMorgan Chase Bank, N.A., Singapore branch (JPMCB Singapore), both of which are regulated by the Monetary Authority of Singapore. This material is issued and distributed in Singapore only to accredited investors, expert investors and institutional investors, as defined in Section 4A of the Securities and Futures Act, Cap. 289 (SFA). This material is not intended to be issued or distributed to any retail investors or any other investors that do not fall into the classes of "accredited investors," "expert investors" or "institutional investors," as defined under Section 4A of the SFA. Recipients of this material in Singapore are to contact JPMS or JPMCB Singapore in respect of any matters arising from, or in connection with, the material. **South Africa:** J.P. Morgan Equities South Africa Proprietary Limited and JPMorgan Chase Bank, N.A., Johannesburg Branch are members of the Johannesburg Securities Exchange and are regulated by the Financial Services Conduct Authority (FSCA). **Taiwan:** J.P. Morgan Securities (Taiwan) Limited is a participant of the Taiwan Stock Exchange (company-type) and regulated by the Taiwan Securities and Futures Bureau. Material relating to equity securities is issued and distributed in Taiwan by J.P. Morgan Securities (Taiwan) Limited, subject to the license scope and the applicable laws and the regulations in Taiwan. According to Paragraph 2, Article 7-1 of Operational Regulations Governing Securities Firms Recommending Trades in Securities to Customers (as amended or supplemented) and/or other applicable laws or regulations, please note that the recipient of this material is not permitted to engage in any activities in connection with the material that may give rise to conflicts of interests, unless otherwise disclosed in the "Important Disclosures" in this material. **Thailand:** This material is issued and distributed in Thailand by JPMorgan Securities (Thailand) Ltd., which is a member of the Stock Exchange of Thailand and is regulated by the Ministry of Finance and the Securities and Exchange Commission, and its registered address is 3rd Floor, 20 North Sathorn Road, Silom, Bangrak, Bangkok 10500. **UK:** Unless specified to the contrary, research is distributed in the UK by J.P. Morgan Securities plc ("JPMS plc") which is a member of the London Stock Exchange and is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. JPMS plc is registered in England & Wales No. 2711006, Registered Office 25 Bank Street, London, E14 5JP. This material is directed in the UK only to: (a) persons having professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) (Order) 2005 ("the FPO"); (b) persons outlined in article 49 of the FPO (high net worth companies, unincorporated associations or partnerships, the trustees of high value trusts, etc.); or (c) any persons to whom this communication may otherwise lawfully be made; all such persons being referred to as "UK relevant persons". This material must not be acted on or relied on by persons who are not UK relevant persons. Any investment or investment activity to which this material relates is only available to UK relevant persons and will be engaged in only with UK relevant persons. Research issued by JPMS plc has been prepared in accordance with JPMS plc's policy for prevention and avoidance of conflicts of interest related to the production of Research which can be found at the following link: [J.P. Morgan EMEA - Research Independence Policy](#). **U.S.:** J.P. Morgan Securities LLC ("JPMS") is a member of the NYSE, FINRA, SIPC, and the NFA. JPMorgan Chase Bank, N.A. is a member of the FDIC. Material published by non-U.S. affiliates is

distributed in the U.S. by JPMS who accepts responsibility for its content.

**General:** Additional information is available upon request. The information in this material has been obtained from sources believed to be reliable. While all reasonable care has been taken to ensure that the facts stated in this material are accurate and that the forecasts, opinions and expectations contained herein are fair and reasonable, JPMorgan Chase & Co. or its affiliates and/or subsidiaries (collectively J.P. Morgan) make no representations or warranties whatsoever to the completeness or accuracy of the material provided, except with respect to any disclosures relative to J.P. Morgan and the Research Analyst's involvement with the issuer that is the subject of the material. Accordingly, no reliance should be placed on the accuracy, fairness or completeness of the information contained in this material. There may be certain discrepancies with data and/or limited content in this material as a result of calculations, adjustments, translations to different languages, and/or local regulatory restrictions, as applicable. These discrepancies should not impact the overall investment analysis, views and/or recommendations of the subject company(ies) that may be discussed in the material. J.P. Morgan accepts no liability whatsoever for any loss arising from any use of this material or its contents, and neither J.P. Morgan nor any of its respective directors, officers or employees, shall be in any way responsible for the contents hereof, apart from the liabilities and responsibilities that may be imposed on them by the relevant regulatory authority in the jurisdiction in question, or the regulatory regime thereunder. Opinions, forecasts or projections contained in this material represent J.P. Morgan's current opinions or judgment as of the date of the material only and are therefore subject to change without notice. Periodic updates may be provided on companies/industries based on company-specific developments or announcements, market conditions or any other publicly available information. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or projections, which represent only one possible outcome. Furthermore, such opinions, forecasts or projections are subject to certain risks, uncertainties and assumptions that have not been verified, and future actual results or events could differ materially. The value of, or income from, any investments referred to in this material may fluctuate and/or be affected by changes in exchange rates. All pricing is indicative as of the close of market for the securities discussed, unless otherwise stated. Past performance is not indicative of future results. Accordingly, investors may receive back less than originally invested. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. This material may include views on structured securities, options, futures and other derivatives. These are complex instruments, may involve a high degree of risk and may be appropriate investments only for sophisticated investors who are capable of understanding and assuming the risks involved. The recipients of this material must make their own independent decisions regarding any securities or financial instruments mentioned herein and should seek advice from such independent financial, legal, tax or other adviser as they deem necessary. J.P. Morgan may trade as a principal on the basis of the Research Analysts' views and research, and it may also engage in transactions for its own account or for its clients' accounts in a manner inconsistent with the views taken in this material, and J.P. Morgan is under no obligation to ensure that such other communication is brought to the attention of any recipient of this material. Others within J.P. Morgan, including Strategists, Sales staff and other Research Analysts, may take views that are inconsistent with those taken in this material. Employees of J.P. Morgan not involved in the preparation of this material may have investments in the securities (or derivatives of such securities) mentioned in this material and may trade them in ways different from those discussed in this material. This material is not an advertisement for or marketing of any issuer, its products or services, or its securities in any jurisdiction.

**Confidentiality and Security Notice:** This transmission may contain information that is privileged, confidential, legally privileged, and/or exempt from disclosure under applicable law. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained herein (including any reliance thereon) is STRICTLY PROHIBITED. Although this transmission and any attachments are believed to be free of any virus or other defect that might affect any computer system into which it is received and opened, it is the responsibility of the recipient to ensure that it is virus free and no responsibility is accepted by JPMorgan Chase & Co., its subsidiaries and affiliates, as applicable, for any loss or damage arising in any way from its use. If you received this transmission in error, please immediately contact the sender and destroy the material in its entirety, whether in electronic or hard copy format. This message is subject to electronic monitoring: <https://www.jpmorgan.com/disclosures/email>

**MSCI:** Certain information herein ("Information") is reproduced by permission of MSCI Inc., its affiliates and information providers ("MSCI") ©2024. No reproduction or dissemination of the Information is permitted without an appropriate license. MSCI MAKES NO EXPRESS OR IMPLIED WARRANTIES (INCLUDING MERCHANTABILITY OR FITNESS) AS TO THE INFORMATION AND DISCLAIMS ALL LIABILITY TO THE EXTENT PERMITTED BY LAW. No Information constitutes investment advice, except for any applicable Information from MSCI ESG Research. Subject also to [msci.com/disclaimer](https://msci.com/disclaimer)

Sustainalytics: Certain information, data, analyses and opinions contained herein are reproduced by permission of Sustainalytics and: (1) includes the proprietary information of Sustainalytics; (2) may not be copied or redistributed except as specifically authorized; (3) do not constitute investment advice nor an endorsement of any product or project; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Sustainalytics is not responsible for any trading decisions, damages or other losses related to it or its use. The use of the data is subject to conditions available at <https://www.sustainalytics.com/legal-disclaimers>. ©2024 Sustainalytics. All Rights Reserved.

"Other Disclosures" last revised July 06, 2024.

**Copyright 2024 JPMorgan Chase & Co. All rights reserved. This material or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan. It is strictly prohibited to use or share without prior written consent from J.P. Morgan any research material received from J.P. Morgan or an authorized third-party ("J.P. Morgan Data") in any third-party artificial intelligence ("AI") systems or models when such J.P. Morgan Data is accessible by a third-party. It is permissible to use J.P.**

Jimmy S. Bhullar, CFA <sup>AC</sup>  
(1-212) 622-6397  
jimmy.s.bhullar@jpmorgan.com

North America Equity Research  
30 July 2024

J.P.Morgan

**Morgan Data for internal business purposes only in an AI system or model that protects the confidentiality of J.P. Morgan Data so as to prevent any and all access to or use of such J.P. Morgan Data by any third-party.**

Completed 30 Jul 2024 08:06 PM EDT

Disseminated 30 Jul 2024 08:15 PM EDT